Arcellx, Inc. Overview
Pro stress-test →Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. The company's core innovation centers on its proprietary D-Domain Affinity Protein T-cell (DAPTI™) platform, which offers a differentiated approach to CAR-T cell therapies with enhanced safety and durability profiles.
Strategic Profile
Pro stress-test →Arcellx is being acquired by Gilead in a $7.8B deal valued at $115 per share plus a $5 CVR tied to $6B anito-cel sales, with an FDA decision date of December 23, 2026 for its lead myeloma CAR-T therapy. The strategic collaboration with Kite Pharma (Gilead subsidiary) involves co-development and co-commercialization of anito-cel, under which Arcellx received substantial upfront payments and is eligible for future milestone payments.
Competitive Landscape
Pro stress-test →Competitors include AbelZeta, Allogene Therapeutics, Senti Bio, Poseida Therapeutics, and Amgen. Arcellx differentiates through its proprietary D-Domain synthetic binder technology, which aims to reduce toxicity and enhance durability versus traditional single-chain variable fragment CAR-T approaches. The Gilead acquisition positions Arcellx as a fully-backed competitor with major commercial infrastructure.
Industry Context
Arcellx, Inc. operates in Biotechnology - Immunotherapy / Cell Therapy.
Key facts
Founded: 2014 · Headquarters: Redwood City, California · Revenue: $35.9M · Market cap: $6.65B